Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoblastic LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupALK+B-ALLCD20+ICD10C82.-C82.7C82.9C83.3C83.5C83.7C84.4C84.6C84.7C85.2C86.1C86.2C86.5C91.0-C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceGMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlySTUDY - levelChemotherapyChemo-substanceAlectinibCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneRituximabVincristineVindesineChemo-substanceAlectinibCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneRituximabVincristineVindesineChemo-substanceAlectinibCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneRituximabVincristineVindesineChemo-substanceAlectinibCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneRituximabVincristineVindesineNo. Substances123467 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances12479101516Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineSecond lineTherapy phaseConsolidationInductionPre-phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlDiarrheaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaInfectionsNeutropeniaOral MucositisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBossi EFukano RHeld GHoelzer DSchmitz NDiseaseaggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3anaplastisches diffus großzelliges B-Zell-Lymphom, ALK+, ZweitlinieHochmaligne B-ALL und B-NHL bei Erwachsenen, Erstlinierezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2Rezidiviertes oder refraktäres diffus großzelliges anaplastisches Lymphom, Zweitlinie, ECOG 0-2OriginDepartment of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanDSHNHL 2002-1German Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaHematology Division, San Gerardo Hospital, Monza, ItalyInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Protocols in Revision 18 protocols foundProtocols under revision.Alectinib 300, diffuse large B-non-Hodgkin Lymphoma (PID2404 V1.0)Crizotinib 250, diffuse large B-non-Hodgkin Lymphoma (PID2403 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346 V1.2)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347 V1.1)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part A, NHL only (PID704 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part B, NHL only (PID705 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID967 V1.2)Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID969 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973 V1.0)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974 V1.0)
